申请人:Glaxo Laboratories, Limited
公开号:US04138555A1
公开(公告)日:1979-02-06
Cephalosporin antibiotics in which the 7.beta.-acylamido group has the structure ##STR1## where R.sup.1 is a furyl, thienyl or phenyl group and R.sup.2 is a C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl or phenyl group and in which the 3-position substituent is a carbamoyloxymethyl group possess a particularly valuable combination of properties, exhibiting high antibacterial activity against a broad range of gram positive and gram negative organisms, paticularly high stablity to .beta.-lactamases produced by various organisms, and stability in vivo. The compounds are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer. Particularly important compounds of this type are (6R,7R)-3-carbamoyloxymethyl-7-[2-(fur-2-yl)-2-methoxyiminoacetamido]ceph- 3-em-4-carboxylic acid (syn isomer) and its non-toxic derivatives, e.g. the sodium salt.
具有以下结构的头孢菌素抗生素,其中7.beta.-acylamido基团的结构为##STR1##其中R.sup.1是呋喃基、噻吩基或苯基,R.sup.2是C.sub.1-C.sub.4烷基、C.sub.3-C.sub.7环烷基或苯基,且3-位置取代基为羰酰氧甲基基团,具有特别有价值的性质组合,对广泛的革兰氏阳性和革兰氏阴性微生物表现出高抗菌活性,特别是对由各种微生物产生的β-内酰胺酶具有高稳定性和体内稳定性。这些化合物是同构体或存在至少90%的同构体和反构体混合物。这种类型的特别重要的化合物是(6R,7R)-3-羰酰氧甲基-7-[2-(呋喃-2-基)-2-甲氧基亚氨基]头孢-3-酮-4-羧酸(同构体)及其非毒性衍生物,例如钠盐。